Lynparza meets primary goal in late-stage study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Lynparza (olaparib) demonstrated statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival in certain tumors.

Lynparza reduced the risk of disease progression or death in the phase III PROfound clinical trial results by a median of 7.4 months versus 3.6 months for those receiving abiraterone or enzalutamide; Lynparza reduced the risk of disease progression or death by 66% for these men.

The drug is being developed by AstraZeneca and Merck.

The trial also met key secondary endpoint of rPFS in overall HRRm population, where Lynparza reduced the risk of disease progression or death by 51% and improved rPFS to a median of 5.8 months versus 3.5 months for those receiving abirateron or enzalutamide.

Secondary endpoint of median time to pain progression was not reached.

PROfound showed a confirmed overall response rate, a key secondary endpoint of 33.3% for Lynparza versus 2.3% for abiratone or enzalutammide in patients with BRCA1/2 or ATM mutations.

Safety and tolerability profile of Lynparza in the PROfound trial was in line with that observed in prior clinical trials.

Table of Contents

YOU MAY BE INTERESTED IN

Credit: Jonah Elkowitz/ShutterstockThat President Biden was diagnosed with prostate cancer is certainly unfortunate news, but it should come as no surprise. One in eight men in the U.S. will be told they have prostate cancer at some point in their lifetime: more than 300,000 new diagnoses occur annually, and the absolute numbers are rising. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login